Coeptis Therapeutics Net Worth
Coeptis Therapeutics Net Worth Breakdown | COEP |
Coeptis Therapeutics Net Worth Analysis
Coeptis Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Coeptis Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Coeptis Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Coeptis Therapeutics' net worth analysis. One common approach is to calculate Coeptis Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Coeptis Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Coeptis Therapeutics' net worth. This approach calculates the present value of Coeptis Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Coeptis Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Coeptis Therapeutics' net worth. This involves comparing Coeptis Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Coeptis Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Coeptis Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Coeptis Therapeutics' net worth research are outlined below:
| Coeptis Therapeutics has some characteristics of a very speculative penny stock | |
| Coeptis Therapeutics had very high historical volatility over the last 90 days | |
| Coeptis Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Coeptis Therapeutics currently holds 1.71 M in liabilities with Debt to Equity (D/E) ratio of 1.89, which is about average as compared to similar companies. Coeptis Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Coeptis Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.57 M) with profit before overhead, payroll, taxes, and interest of 75 K. | |
| Coeptis Therapeutics currently holds about 2.38 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 19.0% of Coeptis Therapeutics shares are held by company insiders | |
| Latest headline from businesswire.com: Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs |
Coeptis Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Coeptis Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Coeptis Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Coeptis Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Coeptis Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Coeptis Therapeutics backward and forwards among themselves. Coeptis Therapeutics' institutional investor refers to the entity that pools money to purchase Coeptis Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hrt Financial Llc | 2024-06-30 | 13 K | Commonwealth Equity Services Inc | 2024-06-30 | 10 K | Tower Research Capital Llc | 2024-06-30 | 9.6 K | Advisor Group Holdings, Inc. | 2024-06-30 | 8.7 K | Bank Of America Corp | 2024-06-30 | 215 | Semmax Financial Advisors Inc. | 2024-06-30 | 112 | Barclays Plc | 2024-06-30 | 67.0 | Sea Otter Advisors Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Creative Planning Inc | 2024-06-30 | 645.1 K | Meteora Capital, Llc | 2024-09-30 | 446.3 K |
Follow Coeptis Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.06 M.Market Cap |
|
Project Coeptis Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.85) | (3.66) | |
| Return On Capital Employed | (4.23) | (4.02) | |
| Return On Assets | (2.63) | (2.50) | |
| Return On Equity | (4.93) | (5.18) |
When accessing Coeptis Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Coeptis Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Coeptis Therapeutics' profitability and make more informed investment decisions.
Evaluate Coeptis Therapeutics' management efficiency
Coeptis Therapeutics has return on total asset (ROA) of (1.8735) % which means that it has lost $1.8735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8129) %, meaning that it created substantial loss on money invested by shareholders. Coeptis Therapeutics' management efficiency ratios could be used to measure how well Coeptis Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/30/2024, Return On Tangible Assets is likely to grow to -3.66. In addition to that, Return On Capital Employed is likely to grow to -4.02. At this time, Coeptis Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 11/30/2024, Liabilities And Stockholders Equity is likely to grow to about 9.6 M, while Non Current Liabilities Total is likely to drop slightly above 1.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.17 | 0.18 | |
| Tangible Book Value Per Share | 0.07 | 0.07 | |
| Enterprise Value Over EBITDA | (0.99) | (0.94) | |
| Price Book Value Ratio | 4.67 | 4.43 | |
| Enterprise Value Multiple | (0.99) | (0.94) | |
| Price Fair Value | 4.67 | 4.43 | |
| Enterprise Value | 19.9 M | 18.9 M |
Coeptis Therapeutics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Quarterly Revenue Growth 15.637 | Return On Equity (14.81) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coeptis Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coeptis Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coeptis Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coeptis Therapeutics time-series forecasting models is one of many Coeptis Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Coeptis Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Coeptis Therapeutics Earnings per Share Projection vs Actual
Coeptis Therapeutics Corporate Management
| Daniel Yerace | VP CoFounder | Profile | |
| Gary Conte | VP Marketing | Profile | |
| David Mehalick | Chairman, CoFounder | Profile | |
| Brian MBA | Chief Officer | Profile | |
| MSc MD | CSO Officer | Profile |
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.